• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Halogenated fatty acids

Research Briefing on 2-Chloro-3-methylpentanoic Acid (CAS: 921-48-2): Recent Advances and Applications

2-Chloro-3-methylpentanoic acid (CAS: 921-48-2) is a chiral carboxylic acid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential as a versatile building block for drug synthesis and its role in studying enzyme mechanisms. Recent studies have explored its applications in asymmetric synthesis, medicinal chemistry, and biocatalysis, highlighting its importance in the development of novel therapeutic agents and biochemical tools.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of 2-chloro-3-methylpentanoic acid as a precursor for the synthesis of γ-aminobutyric acid (GABA) analogs with enhanced blood-brain barrier permeability. The research team utilized a stereoselective enzymatic resolution process to obtain enantiomerically pure forms of the compound, which were subsequently converted into novel GABAergic modulators. These modulators demonstrated promising activity in preclinical models of epilepsy and neuropathic pain, suggesting potential therapeutic applications.

In the realm of biocatalysis, a recent breakthrough was reported in ACS Catalysis (2024), where researchers engineered a novel haloacid dehalogenase capable of selectively cleaving the chlorine moiety from 2-chloro-3-methylpentanoic acid while preserving the stereochemical integrity of the product. This development opens new avenues for the green synthesis of chiral intermediates used in pharmaceutical manufacturing, addressing longstanding challenges in sustainable chemical production.

Structural biology studies have also shed light on the molecular interactions of 2-chloro-3-methylpentanoic acid with various biological targets. Cryo-EM analysis published in Nature Structural & Molecular Biology (2023) revealed that the compound acts as an allosteric modulator of fatty acid-binding proteins (FABPs), potentially offering a new strategy for metabolic disorder treatment. The chlorine substituent was found to play a crucial role in binding affinity and specificity, providing valuable insights for structure-based drug design.

From a safety and regulatory perspective, recent toxicological assessments (2024) have established improved handling guidelines for 2-chloro-3-methylpentanoic acid in industrial settings. These studies, conducted in accordance with OECD guidelines, confirmed that while the compound requires proper protective measures, it presents lower environmental persistence compared to similar halogenated carboxylic acids, making it a more sustainable choice for certain applications.

Looking forward, the unique properties of 2-chloro-3-methylpentanoic acid continue to inspire innovative research directions. Current investigations are exploring its potential in PROTAC (proteolysis targeting chimera) development, where its structural features may facilitate the design of novel protein degraders. Additionally, its application in peptide stapling techniques for stabilizing therapeutic peptide conformations shows particular promise in oncology drug development.

• 32653-34-2((2S,3S)-2-Chloro-3-methylpentanoic Acid)
• 32644-12-5(Pentanoic acid,2-chloro-, (S)- (9CI))
• 56279-49-3(Octadecanoic acid, 2-chloro-)
• 56279-41-5(Nonanoic acid,2-chloro-)
• 30675-03-7(Tricyclo[3.3.1.13,7]decane-1,3-diaceticacid, a1,a3-dichloro-5,7-dimethyl-)
• 4189-03-1(Pentanedioic acid, 2-chloro-)
• 16668-45-4(α-Chloro-3,5,7-Trimethyl-1-Adamantaneacetic Acid)
• 29671-29-2(2-Chloro-4-methylpentanoic acid)
• 28659-81-6((S)-2-Chloro-4-methyl-N-valeric Acid)
• 26782-74-1((S)-2-Chloro-3-methylbutyric acid)